Highest Dose of 20 mg/kg Selected...Clinical Trial to Continue

LG Chem announced that AVEO, which is in charge of the company's U.S. oncology business, has finally selected 20 mg/kg, the highest dose, as the appropriate dose of ficlatuzumab in its ongoing Phase 3 trial and will continue the clinical study.

LG Chem Receives IDMC Recommendation to Continue Phase 3 Trial of New Head and Neck Cancer Drug View original image

This decision was made after the Independent Data Monitoring Committee (IDMC), which has the authority to independently access blinded information during the clinical development process, reviewed the interim results of the Phase 3 trial of ficlatuzumab (FIERCE-HN) and recommended that the clinical trial continue using 20 mg/kg, the highest of the two tested doses, as the final selected dose.


Ficlatuzumab is a monoclonal antibody-based targeted anticancer drug that works by inhibiting the activity of hepatocyte growth factor (HGF), which is involved in tumor growth and metastasis. LG Chem plans to enroll at least 410 and up to 500 patients to evaluate overall survival (OS), the period from initiation of treatment to death. Enrollment is currently proceeding as planned in multiple countries, including Korea, the United States, and Europe.



Son Jeewoong, Head of LG Chem’s Life Sciences Business Division, said, "Building on this meaningful achievement, we will focus our efforts on establishing the clinical value of ficlatuzumab."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing